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Abstract
Background: The purpose of this study was to determine the expected time to prostate specific antigen (PSA)
normalization with or without neoadjuvant androgen deprivation (NAAD) therapy after treatment with intensity
modulated radiotherapy (IMRT) for patients with clinically localized prostate cancer.
Methods: A retrospective cohort research design was used. A total of 133 patients with clinical stage T1c to T3b
prostate cancer (2002 AJCC staging) treated in a community setting between January 2002 and July 2005 were
reviewed for time to PSA normalization using 1 ng/mL and 2 ng/mL as criteria. All patients received IMRT as part
of their management. Times to PSA normalization were calculated using the Kaplan-Meier method. Significance
was assessed at p < 0.05.
Results: Fifty-six of the 133 patients received NAAD (42.1%). Thirty-one patients (23.8%) received radiation to a
limited pelvic field followed by an IMRT boost, while 99 patients received IMRT alone (76.2%). The times to serum
PSA normalization < 2 ng/mL when treated with or without NAAD were 298 ± 24 and 302 ± 33 days (mean ±
SEM), respectively (p > 0.05), and 303 ± 24 and 405 ± 46 days, respectively, for PSA < 1 ng/mL (p < 0.05). Stage T1
and T2 tumors had significantly increased time to PSA normalization < 1 ng/mL in comparison to Stage T3 tumors.
Also, higher Gleason scores were significantly correlated with a faster time to PSA normalization < 1 ng/mL.
Conclusions: Use of NAAD in conjunction with IMRT leads to a significantly shortened time to normalization of
serum PSA < 1 ng/mL in patients with clinically localized prostate cancer.
Background
Prostate cancer is a prominent cause of morbidity and
mortality among men. In 2009, over 190,000 men were
diagnosed and over 25,000 died of this disease in the
United States alone [1]. The utilization of prostate speci-
fic antigen (PSA) screening has resulted in improved
detection of this malignancy in its early stages. Current
management options for localized prostate cancer
include radical prostatectomy, external beam radiation
therapy, brachytherapy, and active surveillance. Both
external beam radiation therapy (EBRT) and
brachytherapy may be combined with neoadjuvant
androgen deprivation therapy (NAAD). While there is
much debate about which modality provides the optimal
treatment for localized disease, radiation therapy with or
without the use of NAAD has been a mainstay of pros-
tate cancer management for many years and has been
studied extensively.
Intensity modulated radiation therapy (IMRT) is a
sophisticated version of 3-dimensional conformal radia-
tion therapy (3D-CRT) which has become widely used
in the United States [2-4]. The ability of IMRT to vary
the intensity of its radiation beam allows for more pre-
cise dose distribution around complex target volumes.
This makes it especially amenable to the treatment of
localized prostate cancer. IMRT has been shown to
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any medium, provided the original work is properly cited.allow for significantly higher doses to the prostate itself,
while simultaneously decreasing the radiation dose to
surrounding normal tissues [5].
A number of studies have shown improvement in out-
come for patients with locally advanced prostate cancer
treated with both external beam radiotherapy and
NAAD [6,7]. However, there is little in the peer-
reviewed literature describing the effect upon PSA nor-
malization of using NAAD in conjunction with IMRT in
prostate cancer. The purpose of this study is to deter-
mine the expected time to PSA normalization with or
without NAAD after treatment with IMRT for patients
with clinically localized prostate cancer.
Methods
Between January 2002 and July 2005, 133 patients with
clinical stage T1c to T3b prostate cancer (using the
2002 AJCC staging system) treated in a community set-
ting were reviewed for time to PSA normalization. All
patients received IMRT as part of their management.
Thirty-one patients (23.5%) received radiation to a lim-
ited pelvic field followed by an IMRT boost, while 99
patients (76.5%) received IMRT alone. Three patients’
boost statuses were not recorded. Treatment planning
was accomplished through the use of multi-slice compu-
terized tomography (CT) scanning of the prostate. The
median prescribed dose to the prostate was 75.6 Gy
given in 1.8 Gy fractions.
For patients that underwent pelvic radiotherapy, a
standard four field box technique was utilized. Simula-
tion took place with the utilization of a customized
immobilization device. 6 or 15 MV photons were uti-
lized. After a dose of 45-50.4 Gy, patients underwent an
IMRT boost. The IMRT technique was the same regard-
less of whether patients received IMRT alone or follow-
ing pelvic radiotherapy. IMRT took place with the
utilization of a customized immobilization device. 6MV
photons were used. Dose was prescribed to the planning
target volume (PTV). The PTV was prescribed at 1.0 cm
around the prostate and seminal vesicles and at 0.6 cm
around rectoprostatic interface.
Fifty-six patients received NAAD therapy in conjunc-
tion with IMRT and 77 received IMRT alone. NAAD
therapy consisted of Lupron (leuprolide) and Casodex
(bicalutamide) for a median treatment length of six
months (range 1 - 26 months). NAAD was given two
months prior and concurrent to radiotherapy as has
been the practice in our clinic.
Serum prostate specific antigen levels were collected
prior to either NAAD therapy or radiation therapy. The
mean pretreatment serum PSA level was 9.5 ± 0.6
(mean ± standard error of the mean [SEM]) ng/mL. All
133 patients had a pre-treatment PSA level drawn as
well as at least one post-treatment PSA level. Patients
who had a pre-treatment PSA level of less than 2 ng/
mL were not included in the 133 patients as they were
already below the decided upon standard for PSA nor-
malization. Time was initiat e df r o mt h es t a r to fr a d i o -
therapy and normalization was assessed during the
follow up period. Patients were followed at months one,
four, and every three months thereafter for the first two
years of the follow up period. Then, patients were
assessed every six months between years two and five
post radiotherapy. At each follow up, patients also
underwent a digital rectal examination. PSA levels were
considered to have normalized at either a PSA of 2 ng/
mL or 1 ng/mL post-treatment. These levels were cho-
sen as these were the standard cutoffs used in our clinic
for time to PSA normalization.
T h eq u a n t i t a t i v ed a t aa r ee x p r e s s e da st h em e a n±
SEM. Ordinal data are expressed as the median, with
the range in parentheses. Times to PSA normalization
were calculated using the Kaplan-Meier method. Differ-
ences between means for quantitative variables for two
or three treatments were analyzed using the two-tailed
t-test or the one way ANOVA, respectively. Associations
between independent variables were performed using
Pearson’s correlation coefficient. The relationship
between Gleason score and time to normalization was
tested using the Spearman correlation coefficient. Signif-
icance was assessed at p < 0.05.
Multivariate analyses utilizing the Cox Proportional
Hazards Model were performed on various hypothesized
predictors of normalization of PSA to below both 2 ng/
mL and 1 ng/mL. Any variable which had a significance
level < 0.2 in the univariate analysis was tested in the
multivariate model. Only variables which tested to be
significant in the regression analysis (p < 0.05) were
included in the final equation.
Results
Table 1 describes the demographic and clinical data
for the subjects. Data for the subjects, related to the
time of normalization of the PSA to less than either 1
ng/mL or 2 ng/mL and related information are on
Tables 2 and 3, respectively. PSA levels were normal-
ized to below 1 ng/mL in 93 of 133 total patients.
Those patients treated with IMRT plus NAAD had a
significantly shorter time to normalization, relative to
the IMRT alone group using PSA normalization to
below 1 ng/mL as an endpoint. PSA levels were nor-
malized to below 2 ng/mL in 119 of the 133 total
patients in the follow-up period. Information on
NAAD was available for 80 of these patients. Those
patients treated with IMRT plus NAAD showed a
s i m i l a rt i m et on o r m a l i z a t i o n ,r e l a t i v et ot h eu s eo f
IMRT alone, with respect to PSA normalization to
below 2 ng/mL as an endpoint.
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assessed as a function of tumor stage (Table 2). Subjects
with stage T2 tumors had the longest time to normali-
zation, followed by subjects with T1 and T3 tumors,
respectively. The time to normalization for the subjects
with T3 tumors was significantly less than for subjects
with the other tumor types.
Time to normalization of PSA below 2 ng/mL was
assessed as a function of tumor stage (Table 3). Subjects
with stage T2 tumors had the longest time to normali-
zation, followed by subjects with T1 and T3 tumors,
respectively. The times to normalization for all three
tumor-type groups were significantly different from one
another.
There were no significant differences seen with respect
to IMRT boost for PSA normalization < 1 ng/mL or for
< 2 ng/mL (Tables 2 and 3). Similarly, there was no sig-
nificant correlation seen within either of these two nor-
malization groups between time to normalization and
either age at time of treatment planning CT, length of
hormone treatment, or pre-treatment PSA levels (pre-
PSA). For the subjects with normalization of PSA to < 2
ng/mL, there was not a significant correlation between
Gleason Score and time to normalization. However,
there was a weakly significant correlation for those sub-
jects with normalization of PSA < 1 ng/mL.
Using the Kaplan-Meier method, times to PSA nor-
malization were calculated, as shown in Figures 1 and 2.
Multivariate analyses were performed using the three
factors found to be statistically significant (for the pur-
poses of this analysis, p < 0.2) for their effect on time to
Table 1 Patient demographic and clinical data
Variable Value
Age (n = 121)* 69.5 ± 0.7
NAAD 56/83 (67.5%)
Time of hormonal treatment (mon; n = 52)* 9.3 ± 1.1
Gleason Score (n = 132)
† 6 (5 - 10)
Pre-PSA (ng/mL)* 9.5 ± 0.6
Unilateral disease 65/117 (55.6%)










Abbreviation: NAAD = Neoadjuvant androgen deprivation therapy; PSA =
Prostate specific antigen; IMRT = intensity modulated radiation therapy
* mean ± SEM
† median (range in parentheses)
Table 2 Data for subjects related to the time of
normalization of PSA < 1 ng/mL
Normalization of PSA to < 1
ng/mL
Time to normalization (d) * (n = 93) 332 ± 18
IMRT with or without NAAD*
With NAAD (n = 49) 303 ± 24
‡
Without NAAD (n = 21) 405 ± 46
‡
IMRT Boost*
Yes (n = 27) 359 ± 34
No (n = 66) 328 ± 22
Tumor Stage*
,§
T1c (n = 70) 329 ± 18 a
T2, T2a, T2b, T2c (n = 16) 440 ± 59 a
T3, T3a, T3b (n = 6) 154 ± 33 b
Correlation to time of normalization
of PSA
†
Age at time of CT (n = 84) 0.01
Length of hormone trt (n = 45) 0.19
Gleason Score (n = 93) -0.22
‡
Pre-PSA (n = 93) -0.13
Abbreviation: PSA = Prostate specific antigen; NAAD = Neoadjuvant androgen
deprivation therapy; IMRT = intensity modulated radiation therapy
* mean ± SEM
† correlation coefficient
‡ p < 0.05
§ values in a column followed by a different letter are significantly different
(p < 0.05)
Table 3 Data for subjects related to the time of
normalization of PSA < 2 ng/mL
Normalization of PSA to < 2
ng/mL
Time to normalization (d) * (n = 119) 289 ± 15
IMRT with or without NAAD*
With NAAD (n = 54) 298 ± 24
Without NAAD (n = 26) 303 ± 33
IMRT Boost*
Yes (n = 28) 308 ± 25
No (n = 91) 283 ± 18
Tumor Stage*
,§
T1c (n = 90) 280 ± 15 b
T2, T2a, T2b, T2c (n = 21) 375 ± 42 a
T3, T3a, T3b (n = 6) 154 ± 33 c
Correlation to time of normalization
of PSA
†
Age at time of CT (n = 108) -0.12
Length of hormone trt (n = 50) 0.22
Gleason Score (n = 119) -0.13
Pre-PSA (n = 119) -0.17
Abbreviation: PSA = Prostate specific antigen; NAAD = Neoadjuvant androgen
deprivation therapy; IMRT = intensity modulated radiation therapy
* mean ± SEM
† correlation coefficient
‡ p < 0.05
§ values in a column followed by a different letter are significantly different
(p < 0.05)
Schmitz et al. Radiation Oncology 2010, 5:80
http://www.ro-journal.com/content/5/1/80
Page 3 of 6PSA normalization < 1 ng/mL: use of IMRT plus NAAD
vs. IMRT alone, tumor stage T2, and Gleason score.
The analysis demonstrated that all three variables were
significant predictors of time to normalization. Hazard
ratios with 95% confidence intervals were calculated for
Stage 2 tumors (2.6; 1.4 - 4.8) and NAAD (0.5; 0.3 -
0.9). A separate analysis was performed for tumor stage
T2 as a predictor for PSA normalization below 2 ng/
mL. Tumor stage T2, as might be expected, showed a
significant hazard ratio of 2.1 (95% CI 1.1 - 4.0).
Discussion
The use of PSA as a tumor marker for prostate cancer is
widespread and well-studied. The use of total serum
PSA to identify patients with prostate cancer has been
well-established since the early 1990 s and has resulted
in a large increase in the detection of early stage pros-
tate cancer [8]. Serum PSA is now widely used as a
marker to determine responses to primary therapy, to
monitor responses to hormonal therapy and to detect
recurrent cancer.
PSA can be used to determine the efficacy of primary
therapy including radical prostatectomy and radiation
therapy. The PSA nadir after radical prostatectomy has
been shown to correlate strongly with recurrence [9].
Patients treated with external beam radiation therapy
quite often still have low but detectable levels of PSA
upon completion of their therapy. Those who demon-
strate three consecutive increases in PSA are considered
to have recurred based upon the American Society of
Therapeutic Radiology and Oncology’s (ASTRO) defini-
tion [10]. Additionally, patients who experience a rise by
2 ng/mL or more above the nadir PSA after external
radiation therapy with or without NAAD are considered
to have biochemical failure according to the RTOG-
ASTRO Phoenix definition [11].
Similarly, serum PSA can be utilized to determine
response to hormonal therapy. Patients treated with
androgen deprivation therapy often have dramatically
reduced levels of PSA upon completion of their therapy.
This decrease in PSA level has been shown to coincide
with improved clinical symptoms in prostate cancer
patients. Also, a PSA nadir of less than 0.4 ng/mL has
been shown to be correlated with the duration of remis-
sion [12].
Our findings point to three distinct factors that appear
to be involved in affecting the time to normalization of
PSA after treatment for clinically localized prostate can-
cer with IMRT: tumor stage, Gleason score, and the use
of NAAD therapy.
PSA levels normalized below both 2 ng/mL and 1 ng/
mL at a much slower rate when the tumor being treated
was a stage T2 tumor rather than when the tumor was
stage T1 or T3. Patients with stage T2 tumors had an
average time to normalization of 95 days longer than
patients with stage T1 tumors and 221 days longer than
patients with stage T3 tumors when normalizing to PSA
< 2 ng/mL. Similarly, patients with stage T2 tumors had
an average time to normalization to PSA < 1 ng/mL of
111 days longer than those with stage T1 tumors and
286 days longer than those with stage T3 tumors.
The difference in time to normalization of PSA < 2
ng/mL between stages T1, T2, and T3 was statistically
significant. It could be hypothesized that those patients
with stage T2 disease possess a different biologic pheno-
type that reacts more rapidly to androgen deprivation. It
may be true that stage T3 cancers are more dispersed
so as to allow a greater interaction between those malig-
nant cells that make up the tumor and the circulating
anti-androgen affects of the therapy. With a more exten-
sive and richer connection to systemic blood supplies,
the stage T3 tumor may also be more susceptible to the




























Figure 1 Kaplan-Meier curve detailing the time for
normalization of PSA to less than 1 ng/ml.




























Figure 2 Kaplan-Meier curve detailing the time for
normalization of PSA to less than 2 ng/ml.
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tively, potentially being more de-differentiated, T3
tumors may respond more rapidly to NAAD.
The T1 tumors also show a relative susceptibility to
PSA normalization in comparison with T2 tumors.
There is potentially a different explanation as to why
they are more susceptible. Having less tumor burden,
there is potentially a greater chance that T1 patients will
undergo apoptotic cell death due to androgen depriva-
tion to cause a significantly faster normalization of PSA
level. The T2 tumors may have invaded to the point
that a certain percentage of malignant cells will simply
be untreated by the affects of androgen deprivation, but
have not invaded to the point where their increased
access to the systemic blood supply results in greater
susceptibility to the anti-androgen affects of the therapy.
Overall, it is difficult to make definitive conclusions
regarding T stage and rate of PSA normalization, as
only 5% of our sample had T3 disease and 15% had T2
disease.
Our data also showed a statistically significant correla-
tion between the Gleason score of a tumor and the rate
of PSA normalization to below 1 ng/mL, but not to
below 2 ng/mL. This may possibly be explained by the
fact that the cells that comprise a tumor with a high
Gleason score are, by definition, less differentiated. It
has been well documented that tumors of a higher Glea-
son score are made up of cells that actually produce less
PSA per cell [13,14]. It then would follow that androgen
deprivation therapy could very well have a more pro-
found impact on the PSA production abilities of cells
that were already less differentiated.
Finally, our data demonstrate that patients treated
with IMRT plus NAAD normalized to a serum PSA
level below 1 ng/mL 102 days earlier than those patients
treated with IMRT alone. This effect was not significant
when the level of PSA normalization was set at less than
2 ng/mL. It is possible that the use of NAAD therapy
acts as a radiosensitizer in areas of the tumor mass. It is
also possible that the androgen deprivation therapy is
causing apoptotic cell death, as well as surviving tumor
cells to cease production of PSA.
When androgen deprivation therapy is implemented,
there is a subsequent apoptotic death of large numbers
of cancerous prostate cells. This results in a significant
decrease in the serum PSA level due to decreased pro-
static cell mass. However, it has been shown that
because transcription of the PSA gene is regulated by an
androgen receptor, not all of this serum PSA decrease is
due to cell death. Some surviving tumor cells are simply
blocked from producing PSA because of the lack of
androgen available to stimulate transcription of the PSA
gene [15,16]. This phenomenon may also explain in part
the significantly shorter time to PSA normalization
when androgen deprivation therapy is combined with
IMRT.
Serum PSA levels are routinely used today as a mea-
sure of a therapy’s impact on prostate cancer. With
such a significantly quicker normalization of PSA when
neoadjuvant hormone therapy is used in conjunction
with IMRT, this may constitute a reason to think more
seriously about expanding the role of NAAD therapy in
these patients. Further study is needed to elucidate
whether the rate of PSA normalization is linked to nota-
ble endpoints such as mortality or disease recurrence. If
it is found that a faster rate of PSA normalization to a
level below 1 ng/mL is associated with decreased mor-
tality or disease recurrence rates, then the use of NAAD
therapy may need to be expanded to men with clinically
localized disease.
Some work in this area has been done with some con-
flicting results. In a very large study that showed the
importance of PSA normalization, Collette et al.
assessed whether PSA could serve as a surrogate end-
point for survival [17]. They showed that, using a PSA
normalization value of 4 ng/mL, those patients who nor-
malized showed 4.9-fold greater odds of surviving than
those patients who did not normalize. While this does
not directly attest to the importance of the rate of PSA
normalization, given the nearly 5-fold greater odds of
survival for those patients achieving normalization,
achieving that goal would be of significance.
Of additional concern is whether reduced time to PSA
nadir is related to more positive outcomes. Chung et al.
noted that, for PSA nadir values > 0.9 mg/mL, increased
time to PSA nadir was associated with increased pros-
tate cancer specific mortality and all causes mortality,
relative to men with a time to PSA nadir < four months
[18]. Conversely, both Ray et al. and Hori et al. have
shown a direct relationship between positive outcomes
and a decreased time to PSA nadir [19,20]. In our
cohort, we did not correlate time to PSA normalization
with clinical outcome.
Additionally, our data showed no significant relation-
ship between the rate of normalization of PSA and the
duration of NAAD therapy. Previous studies have
attempted to determine the optimal duration of androgen
deprivation therapy for men with clinically localized
prostate cancer. One large study by Crook, et al. showed
no difference in overall survival, disease-free survival, or
rates of recurrence between two groups of men with
clinically localized prostate cancer treated with either 3
or 8 months of neoadjuvant androgen deprivation ther-
apy [21]. The same study, however, did show a difference
in disease free survival among men with high risk disease.
A number of other studies have also shown that, at least
in men with high risk clinically localized disease, there
may be significant benefits to a longer duration of
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have shown conflicting results in terms of whether the
duration of androgen deprivation therapy has any true
effect on mortality and disease recurrence rates.
Conclusions
In summary, our results show that the use of neoadjuvant
androgen deprivation therapy (NAAD) in conjunction
with intensity modulated radiation therapy (IMRT) leads
to a significantly shorter time to serum prostate specific
antigen (PSA) normalization (less than 1 ng/mL) than
the use of IMRT alone in the treatment of clinically loca-
lized prostate cancer. Also, factors leading to a shorter
time to PSA normalization after IMRT treatment for
clinically localized prostate cancer include tumor stages
T1 and T3 and a higher tumor Gleason score.
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